ArticleEBioMedicine2026
Sebum-associated type 17 inflammation in atopic dermatitis: a single-cell and in vivo study of body-site immune heterogeneity.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory skin diseases exhibit striking anatomical predilections, yet the mechanisms shaping site-specific immune programs remain poorly understood. Although atopic dermatitis (AD) is classically considered a type 2-driven disease, lesions arising in sebum-rich skin such as the face often show suboptimal responses to type 2-targeting biologics, suggesting the presence of distinct site-specific immune programs shaped by the local tissue environment.
methodsWe performed single-cell RNA sequencing (scRNA-seq) on matched facial and popliteal lesions from adult male patients with AD (n = 3 facial lesions, n = 3 popliteal lesions) to characterize site-specific immune landscapes. MC903-induced AD mouse models were used to investigate the effects of topical sebum on cutaneous inflammation, with mechanistic studies focusing on macrophage lipid metabolism and inflammatory signaling assessed by flow cytometry, quantitative PCR, and pharmacological inhibition approaches.
findingsscRNA-seq analysis revealed enhanced type 17-associated immune signatures in facial AD lesions relative to matched popliteal lesions, despite preservation of type 2 inflammatory features. In mouse models, topical sebum selectively amplified Th17 responses through FABP5-dependent induction of macrophage IL-1β production. Sebum also reduced the therapeutic response to Th2 blockade, accompanied by further enhancement of type 17 inflammation. Pharmacological inhibition of FABP5 attenuated sebum-induced immune deviation and reduced disease severity.
interpretationThese findings suggest that a sebum-associated macrophage metabolic axis contributes to type 17-skewed inflammation in sebaceous skin regions, providing a mechanistic framework for understanding anatomical immune heterogeneity and highlighting potential targets for modulating site-specific inflammation.
fundingThe National Natural Science Foundation of China; Natural Science Foundation of Zhejiang Province; China Postdoctoral Science Foundation; Natural Science Foundation of Hubei Province; Bethune Charitable Foundation; Wuhan Municipal Natural Science Foundation; Wuhan Municipal Health Commission; The Shanghai Municipal Commission of Health and Family Planning; The Program of Shanghai Academic/Technology Research Leader.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.